三生制药
3SBIO INC.

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 01530)

COMPLETION OF SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE

Reference is made to the announcement of the Company dated 24 July 2025 in relation to the subscription of new Shares under the General Mandate (the "**Announcement**"). Unless the context requires otherwise, terms defined in the Announcement shall have the same meaning when used in this announcement.

COMPLETION OF SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE

The Board is pleased to announce that all the conditions precedent for the Subscription have been fulfilled and Completion took place on 1 August 2025. A total of 31,142,500 Subscription Shares have been successfully issued to Pfizer at the Subscription Price of HK$25.2055 per Subscription Share. The Subscription Shares represent (i) approximately 1.30% of the existing issued share capital of the Company immediately before Completion; and (ii) approximately 1.28% of the issued share capital of the Company as enlarged by the issue and allotment of the Subscription Shares.

The aggregate gross proceeds from the Subscription amounted to approximately HK$785.0 million. The aggregate net proceeds from the Subscription, after deduction of relevant costs and expenses, amounted to approximately HK$785.0 million. As disclosed in the Announcement, the Company intends to use (i) approximately HK$628.0 million (representing 80% of the net proceeds) for the global R&D arrangement of clinical and preclinical programs in the rich pipeline, as well as for enhancing manufacturing facilities; and (ii) approximately HK$157.0 million (representing 20% of the net proceeds) for other general corporate purposes.

EFFECT ON SHAREHOLDING STRUCTURE

The shareholding structure of the Company (i) immediately before Completion; and (ii) immediately after Completion, are as follows:

Name of Shareholders	Immediately before Completion		Immediately after Completion	
	Number of Shares	Approximate shareholding percentage[7]	Number of Shares	Approximate shareholding percentage[7]
Substantial Shareholders, directors of the Group and their close associates				
Decade Sunshine Limited[1]	476,774,553	19.86	476,774,553	19.60
Hero Grand Management Limited[2]	51,156,895	2.13	51,156,895	2.10
Dr. LOU Jing[3]	5,311,553	0.22	5,311,553	0.22
Ms. SU Dongmei	24,384,630	1.02	24,384,630	1.00
Ms. ZHANG Jiaoe	12,299,139	0.51	12,299,139	0.51
Mr. YU An[4]	650,000	0.03	650,000	0.03
Mr. JIN Zheng[5]	600,000	0.02	600,000	0.02
An employee benefit trust[6]	15,340,480	0.64	15,340,480	0.63
Public Shareholders				
Pfizer	–	–	31,142,500	1.28
Other public Shareholders	1,814,606,162	75.57	1,814,606,162	74.61
Total	**2,401,123,412**	**100.00**	**2,432,265,912**	**100.00**

Notes:

(1) A trust, which Dr. LOU Jing (Chairman of the Board) is an enforcer and is under the class of beneficiaries of, indirectly holds these 476,774,553 Shares via Decade Sunshine Limited.

(2) Two trusts, which Dr. LOU Jing is a beneficiary of, hold these 51,156,895 Shares in aggregate via Hero Grand Management Limited.

(3) It comprises (i) 311,553 Shares held by Dr. LOU Jing as beneficial owner, and (ii) 5,000,000 Shares representing share awards granted to Dr. LOU Jing, which are held by the trustee of the 2019 Share Award Scheme. These share awards remain subject to certain vesting criteria and conditions as of the date of this announcement.

(4) Mr. YU An is a director of a subsidiary of the Company. These 650,000 Shares represent share awards granted to Mr. YU An, which are held by the trustee of the 2019 Share Award Scheme. These share awards remain subject to certain vesting criteria and conditions as of the date of this announcement.

(5) Mr. JIN Zheng is a general manager of a subsidiary of the Company. These 600,000 Shares represent share awards granted to Mr. JIN Zheng, which are held by the trustee of the 2019 Share Award Scheme. These share awards remain subject to certain vesting criteria and conditions as of the date of this announcement.

(6) A trust, the beneficiaries of which are employees of the Company and other persons declared by the advisory committee of the trust and/or the trustee, indirectly holds these 15,340,480 Shares via Medical Recovery Limited. As of the date of this announcement, Dr. LOU Jing and Ms. SU Dongmei (an executive Director) are two out of four members of the advisory committee.

(7) The percentages are subject to rounding difference, and figures shown as totals may not be an arithmetic aggregation of the figures preceding them, if any.

By order of the Board
3SBio Inc.
Dr. LOU Jing
Chairman

Shenyang, the PRC
1 August 2025

As at the date of this announcement, the Board comprises Dr. LOU Jing and Ms. SU Dongmei as executive Directors; Ms. ZHANG Jiaoe as non-executive Director; and Mr. PU Tianruo, Ms. YANG Hoi Ti Heidi and Mr. NG, Joo Yeow Gerry as independent non-executive Directors.